[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340716-105":59,"doc-detail-340716-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","car-t-cell-therapy-based-on-immune-checkpoint-modulation-in-the-treatment-of-hematologic-malignancies","CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies","","Chimeric antigen receptor (CAR) T-cell therapy provides substantial benefit for selected hematologic malignancies, yet it faces limitations and not all patients respond with CAR-T therapy alone. Modulating CAR-T-cell function through immune checkpoint pathways and combining it with immune checkpoint inhibitors (ICIs) offers a more effective therapeutic direction. The article reviews progress from preclinical research to clinical trials, detailing how checkpoint modulation may enhance efficacy and address unmet needs in treating hematologic cancers.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/car-t-cell-therapy-based-on-immune-checkpoint-modulation-in-the-treatment-of-hematologic-malignancies/340716/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/car-t-cell-therapy-based-on-immune-checkpoint-modulation-in-the-treatment-of-hematologic-malignancies/340716.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"How do immune checkpoints contribute to immune evasion in hematologic cancers?","Question",{"text":112,"@type":113},"Immune checkpoints increase during exhaustion of CD8+ T cells and NK cells and act as inhibitory brakes by interacting with ligands on antigen-presenting cells, cancer cells, and the tumor microenvironment, weakening anti-neoplastic activity.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},340716,1790652347,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":19,"preview_urls":138},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies  \nManqi Su 1, Zhanna Zhang 1, Panruo Jiang 1, Xiaoxia Wang 1, Xiangmin Tong2*, and Gongqiang Wu 1*  \nCell Transplantation Volume 33: 1–11  \n© The Author(s) 2024  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/09636897241293964](DOI: 10.1177/09636897241293964)[ ](DOI: 10.1177/09636897241293964)[journals.sagepub.com/home/cll](journals.sagepub.com/home/cll)  \nAbstract  \nChimeric antigen receptor (CAR) T-cell therapy is a revolutionary immunotherapy that has shown significant success in treating certain hematologic malignancies. However, there are still challenges and limitations associated with this therapy, and not all cancer patients benefit from this therapy alone. Therefore, modifying CAR-T-cell therapy based on immune checkpoints, and its combination with immune checkpoint inhibitors (ICIs), shows promise as a potentially more effective strategy for treating hematologic malignancies. This article outlines the progress of preclinical and clinical trials of CAR-T-cell therapy based on immune checkpoint modulation in the treatment of hematologic malignancies.  \nKeywords  \nICI, ICP, CAR-T-cell therapy, hematological malignancies, immunotherapy  \nGraphical Abstract  \nCheckpoint signaling interactions and pathways between tumor and immune cells.  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons AttributionNonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and  \ndistribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)).  \nIntroduction  \nTraditionally, the treatment of hematologic malignancies involved chemotherapy, radiotherapy, hematopoietic stem cell transplantation (HSCT), and targeted therapies. However, with continuous progress in cancer treatment, particularly the advent of chimeric antigen receptor (CAR) T-cell therapy, the landscape of treatment options for hematologic malignancy therapy has been revolutionized; this approach has achieved unprecedented success in recent years, especially in the treatment of B-cell acute lymphoblastic leukemia (B-ALL), with complete remission rates ranging from 70% to 90%1,2 . Although CAR-Tcell therapy holds promise for novel therapeutic approaches in oncology, it may also trigger some serious adverse effects. Some patients may suffer from cytokine release syndrome (CRS)3, neurotoxicity4, and on-target off-tumor toxicity5, which can be life-threatening in extreme cases. In addition, although some patients will improve at the beginning of treatment, they may ultimately experience disease relapse factors such as genetic mutations, transient survival of CAR-T cells, immunogenicity of CAR-T cells themselves, tumor infiltration limits, related antigen escape, and CAR-T-cell depletion or immunosuppression microenvironment6. These challenges underscore the imperative to continue exploring alternative approaches to improve efficacy, mitigate side effects, and prolong the duration of therapy while advancing CAR-T-cell therapy. Therefore, seeking an approach to combine CAR-T-cell therapy with other treatment modalities is imperative.  \nCancer cells tend to evade immune surveillance and resist destruction through various mechanisms. Immune evasion by cancer cells is of vital importance in the initiation, development, drug resistance, and poor prognosis of neoplasms. The mechanism underlying immunosuppression involves a multifaceted series of steps and factors, with the exhaustion of immune cells specialized in cell destruction, inclu","cbCailkQSclalgqT","https://ap.wps.com/l/cbCailkQSclalgqT","pdf",636657,11,"English","# Abstract\n# Introduction\n## Current therapeutic landscape for hematologic malignancies\n## Adverse effects and relapse mechanisms of CAR-T-cell therapy\n## Immune checkpoint proteins and immune evasion\n## Rationale for immune checkpoint inhibitors and variability of response","[{\"question\":\"How do immune checkpoints contribute to immune evasion in hematologic cancers?\",\"answer\":\"Immune checkpoints increase during exhaustion of CD8+ T cells and NK cells and act as inhibitory brakes by interacting with ligands on antigen-presenting cells, cancer cells, and the tumor microenvironment, weakening anti-neoplastic activity.\"}]","CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies | PDF",1790038410,28,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78bf72a1b4780a4555a2005577e2adeb.webp",983,1272,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4bb42a3c98e24ec1dc6e8e0761f182e.webp",982,1270,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56c69f5152dfec8b321b8a616703c6f5.webp",981,1269,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f348e48a89335f4462723cef00085cb3.webp",980,1268]